1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Analysis of Gilead Sciences

Analysis of Gilead Sciences

  • April 2016
  • -
  • Aruvian's R'search
  • -
  • 120 pages

Summary

Table of Contents

Search Inside

Based in the United States, Gilead Sciences is a global leader in the marketing and development of anti-infective drugs. The company has approved products for the treatment of Hepatitis B & C, HIV/AIDS, fungal infections and influenza.

Aruvian Research presents Analysis of Gilead Sciences. A complete and comprehensive analysis of Gilead Sciences, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvian includes a history of Gilead Sciences, a business segment analysis of the segments Gilead Sciences operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Gilead Sciences is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Gilead Sciences completes this in-depth company analysis.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...

Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application ((HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded)), And Segment Forecasts, 2014 - 202

Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application ((HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded)), And Segment Forecasts, 2014 - 202

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025, based on a new report by Grand View Research, Inc. According to the WHO, cases of viral infections increase by ...

Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2017 - 2022)

Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

In 2016, the global antiviral market was estimated to be worth USD 30.84 billion and is expected to reach revenues of approximately USD 40.71 billion by 2022 at a CAGR of 5.71% between 2016 and 2022. The ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.